TJ101

TJ101 is a first-in-class bispecific antibody-drug conjugate (ADC) developed by Phrontline Biopharma, targeting both Epidermal Growth Factor Receptor (EGFR) and B7-H3 (CD276). It utilizes a proprietary cleavable linker to attach a novel topoisomerase I inhibitor payload. By targeting two distinct tumor-associated antigens, TJ101 is designed to enhance tumor selectivity and overcome resistance mechanisms associated with single-target ADCs. Upon binding and internalization into tumor cells, the payload is released via enzymatic cleavage in lysosomes, leading to DNA damage and cell death, while also exerting a bystander effect on neighboring tumor cells. It is currently being evaluated in Phase 1 clinical trials for advanced solid tumors, including non-small cell lung cancer, prostate cancer, and esophageal cancer.